EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35–40 years

Alexandra P Bielfeld, Juan-Enrique Schwarze, Patrice Verpillat, Monica Lispi, Robert Fischer, Brooke Hayward, Dana Chuderland, Thomas D'Hooghe, Jan-Steffan Krussel

Reproductive BioMedicine Online · 2024-06 · 48 (6) · 103725

DOI: 10.1016/j.rbmo.2023.103725 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Reproductive BioMedicine Online, 2024-06. Verfasst von Alexandra P Bielfeld und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics/Gynecology and Reproductive Medicine, UniKiD Center for Reproductive Medicine (UniKiD), Medical Faculty and University Hospi…. Hauptthemen laut MEDLINE: Recombinant Proteins, Ovulation Induction, Follicle Stimulating Hormone, Human, Luteinizing Hormone. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Healthcare KGaA, Merck KGaA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RESEARCH QUESTION: According to real-world data, is recombinant human FSH (r-hFSH) combined with recombinant human LH (r-hLH) or r-hFSH alone more effective for women of advanced maternal age (AMA) in terms of live birth? DESIGN: Non-interventional study comparing the effectiveness of r-hFSH and recombinant r-hLH (2:1 ratio) versus r-hFSH alone for ovarian stimulation during ART treatment in women aged 35-40 years, using real-world data from the Deutsches IVF-Register. RESULTS: Overall clinical pregnancy (29.8%, 95% CI 28.2 to 31.6 versus 27.8%, 95% CI 26.5 to 29.2) and live birth (20.3%, 95% CI 18.7 to 21.8 versus 18.0%, 95% CI 16.6 to 19.4) rates were not significantly different between the combined r-hFSH and r-hLH group and the r-hFSH alone group (P = 0.269 and P = 0.092, respectively). Treatment effect was significantly higher for combined r-hFSH and r-hLH compared with r-hFSH alone for clinical pregnancy (33.1%, 95% CI 31.0 to 35.0 versus 28.5%, 95% CI 26.6 to 30.4; P = 0.001, not adjusted for multiplicity) and live birth (22.5%, 95% CI 20.5 to 24.2 versus 19.4%, 95% CI 17.6 to 20.9; P = 0.014, not adjusted for multiplicity) in a post-hoc analysis of women with five to 14 oocytes retrieved (used as a surrogate for normal ovarian reserve), highlighting the potential benefits of combined r-hFSH and r-hLH for ovarian stimulation in women aged 35-40 years with normal ovarian reserve. CONCLUSIONS: Women of AMA with normal ovarian response benefit from treatment with combined r-hFSH and r-hLH in a 2:1 ratio versus r-hFSH alone in terms of live birth rate. The effectiveness of treatments is best assessed by RCTs; however, real-world data are valuable for examining the effectiveness of fertility treatment, especially among patient groups that are not well represented in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant ProteinsOvulation InductionFollicle Stimulating Hormone, HumanLuteinizing HormoneHumansFemalePregnancyAdultPregnancy RateReproductive Techniques, AssistedDrug Therapy, CombinationTreatment OutcomeLive Birth

Stichwörter der Autor:innen

advanced maternal ageclinical pregnancylive birthovarian stimulationr-hFSH: r-hLHreal-word data

Substanzen

Recombinant ProteinsFollicle Stimulating Hormone, HumanLuteinizing Hormone

Autor:innen und Institutionen

  • Department of Obstetrics/Gynecology and Reproductive Medicine, UniKiD Center for Reproductive Medicine (UniKiD), Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine University, Universitätsstraße 1, 40225…
  • Global Medical Affairs Fertility, Merck Healthcare KGaA, Frankfurter Strasse 250, Darmstadt, 64293, Germany. Electronic address: juan-enrique.schwarze@merckgroup.com.
  • Global Epidemiology, Merck Healthcare KGaA, Frankfurter Strasse 250, Darmstadt, 64293, Germany.
  • Global Medical Affairs Fertility, Merck Healthcare KGaA, Frankfurter Strasse 250, Darmstadt, 64293, Germany; PhD School of Clinical and Experimental Medicine, Unit of Endocrinology, University of Modena and Reggio Emili…
  • Fertility Centre Hamburg, 20095 Hamburg, Germany.
  • EMD Serono, One Technology Place, Rockland, Massachusetts, 02370, USA, an affiliate of Merck KGaA, Darmstadt, Germany.

Förderung

  • Merck Healthcare KGaA
  • Merck KGaA

Zitieren

APA

Bielfeld, A. P., Schwarze, J. E., Verpillat, P., Lispi, M., Fischer, R., Hayward, B., Chuderland, D., D'Hooghe, T., & Krussel, J. S. (2024). Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35–40 years. Reproductive BioMedicine Online, 48(6), 103725. https://doi.org/10.1016/j.rbmo.2023.103725

Vancouver

Bielfeld AP, Schwarze JE, Verpillat P, Lispi M, Fischer R, Hayward B, et al. Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35–40 years. Reproductive BioMedicine Online. 2024;48(6):103725. doi:10.1016/j.rbmo.2023.103725

BibTeX
@article{Bielfeld2024,
  author = {Bielfeld, Alexandra P and Schwarze, Juan-Enrique and Verpillat, Patrice and Lispi, Monica and Fischer, Robert and Hayward, Brooke and Chuderland, Dana and D'Hooghe, Thomas and Krussel, Jan-Steffan},
  title = {Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35–40 years},
  journal = {Reproductive BioMedicine Online},
  year = {2024},
  volume = {48},
  number = {6},
  pages = {103725},
  doi = {10.1016/j.rbmo.2023.103725}
}
Kostenlos starten →